Şenol Kobak

1.3k total citations
88 papers, 796 citations indexed

About

Şenol Kobak is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Şenol Kobak has authored 88 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Physiology, 33 papers in Pulmonary and Respiratory Medicine and 33 papers in Rheumatology. Recurrent topics in Şenol Kobak's work include Sarcoidosis and Beryllium Toxicity Research (36 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (28 papers) and Spondyloarthritis Studies and Treatments (15 papers). Şenol Kobak is often cited by papers focused on Sarcoidosis and Beryllium Toxicity Research (36 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (28 papers) and Spondyloarthritis Studies and Treatments (15 papers). Şenol Kobak collaborates with scholars based in Türkiye, United States and Italy. Şenol Kobak's co-authors include Mehmet Orman, Cemal Beş, Yasemin Kabasakal, Fahrettin Öksel, Eker Doğanavşargil, Kenan Aksu, Özlem İnce, Afig Berdelı, Gökhan Keser and Bahadır Kırılmaz and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Medicine.

In The Last Decade

Şenol Kobak

82 papers receiving 777 citations

Peers

Şenol Kobak

RHEUM

PHYSI

PRM

IMMUN

Stéphan Pavy France

Susan Lester Australia

Murat Turgay Türkiye

Norma Nardi Spain

Arnulfo Hernán Nava-Zavala Mexico

Pascal Bindi France

Teresa Iwaniec Poland

Naoto Yokogawa Japan

Jonathan London France

Catherine Veyssier-Belot France

Stéphan Pavy France

Şenol Kobak

604 ×1.7

RHEUM

200 ×0.6

PHYSI

139 ×0.5

PRM

220 ×1.8

IMMUN

87 ×0.7

Citations per year, relative to Şenol Kobak Şenol Kobak (= 1×) peers Stéphan Pavy

Countries citing papers authored by Şenol Kobak

Since Specialization

Citations

This map shows the geographic impact of Şenol Kobak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Şenol Kobak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Şenol Kobak more than expected).

Fields of papers citing papers by Şenol Kobak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Şenol Kobak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Şenol Kobak. The network helps show where Şenol Kobak may publish in the future.

Co-authorship network of co-authors of Şenol Kobak

This figure shows the co-authorship network connecting the top 25 collaborators of Şenol Kobak. A scholar is included among the top collaborators of Şenol Kobak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Şenol Kobak. Şenol Kobak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobak, Şenol, et al.. (2023). Increased circulating interleukin-23 level in patients with sarcoidosis. Reumatología Clínica. 19(9). 478–481.

Kobak, Şenol, et al.. (2023). Atezolizumab Lung Toxicity: Importance of Combination Treatment OnThe Edge of Life, A Case Report. Current Drug Safety. 19(4). 469–473.

Öncel, Güray, et al.. (2023). The role of chest X-ray in the early diagnosis and staging of sarcoidosis: Is it really should be done?. Reumatología Clínica. 19(10). 560–564. 1 indexed citations

Kobak, Şenol. (2023). Stairway to Heaven: Do head-to-head Trials Indicate a Need for DefiniteCriteria for Choosing Biologic Drugs in Rheumatoid Arthritis?. Current Rheumatology Reviews. 19(4). 408–419. 1 indexed citations

Kobak, Şenol. (2023). VEXAS syndrome: Current clinical, diagnostic and treatment approaches. Intractable & Rare Diseases Research. 12(3). 170–179. 9 indexed citations

Kobak, Şenol. (2023). Treat to target and tight control: Could be a new approach in the treatment of sarcoidosis?. Intractable & Rare Diseases Research. 12(1). 22–28. 1 indexed citations

Kobak, Şenol, et al.. (2022). Serum salusin-α and salusin-β levels in patients with psoriatic arthritis. Reumatologia/Rheumatology. 60(5). 306–310. 3 indexed citations

Kobak, Şenol, et al.. (2021). Serum galectin-3 and TGF-beta levels in patients with sarcoidosis. Reumatología Clínica (English Edition). 17(10). 562–565. 3 indexed citations

Kobak, Şenol. (2020). The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection. Current Rheumatology Reviews. 17(2). 141–152. 2 indexed citations

10.

Kobak, Şenol. (2020). Tofacitinib-induced Ramsay- Hunt Syndrome in a Patient with Rheumatoid Arthritis. Current Drug Safety. 16(1). 107–109. 3 indexed citations

11.

Kobak, Şenol. (2020). Secukinumab-induced Raynaud’s phenomenon: first report in the literature. Therapeutic Advances in Drug Safety. 11. 585447928–585447928. 5 indexed citations

12.

Kobak, Şenol, et al.. (2020). Serum galectin-3 and TGF-beta levels in patients with sarcoidosis. Reumatología Clínica. 17(10). 562–565. 4 indexed citations

13.

Kobak, Şenol, et al.. (2017). Coexistence of Sarcoidosis and Gouty Arthritis. Reumatología Clínica. 15(6). e105–e107. 2 indexed citations

14.

Kobak, Şenol, et al.. (2015). Co-occurrence of rheumatoid arthritis and sarcoidosis. BMJ Case Reports. 2015. bcr2014208803–bcr2014208803. 9 indexed citations

15.

Kobak, Şenol, et al.. (2013). The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis. SHILAP Revista de lepidopterología. 2013. 1–4. 3 indexed citations

16.

Kobak, Şenol, et al.. (2013). Coexistence of Sarcoidosis and Systemic Sclerosis. SHILAP Revista de lepidopterología. 2013. 1–3. 12 indexed citations

17.

Kobak, Şenol, et al.. (2013). Scleroderma renal crisis and ovarian hyperstimulation syndrome related to the use of clomiphene in a patient with scleroderma. Reumatología Clínica. 10(1). 51–53. 1 indexed citations

18.

Kobak, Şenol & Afig Berdelı. (2012). Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis. Reumatismo. 64(6). 374–9. 10 indexed citations

19.

Kobak, Şenol. (2010). Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatology International. 32(6). 1785–1787. 13 indexed citations

20.

Kobak, Şenol, et al.. (2006). Tumor necrosis factor-alpha gene promoter polymorphism in patients with familial Mediterranean fever. Clinical Rheumatology. 26(6). 908–910. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact